

NEWS RELEASE

July 15, 2026

LinDo K.K., Signs Licensing Agreement with Proveca Ltd. to Develop and Commercialize
Sialanar® in Japan for the treatment of Sialorrhea in Paediatric Patients with Chronic
Neurological Disorders

~ Addressing the Challenge of 'Drug Loss' and Ensuring Access to Innovative Medicines
in Japan ~

TOKYO and MANCHESTER, July 15, 2026 – LinDo K.K. ("LinDo"; Head Office: Tokyo, Japan, President: Jun Katsura) and Proveca Ltd. ("Proveca"; Head Office: Manchester, UK; CEO: Dr Simon Bryson) today announced that they have entered into an exclusive license agreement for the development and commercialization of Glycopyrronium Bromide Oral Solution, (marketed globally as Sialanar®; hereinafter referred to as the "Product") in Japan. Under the terms of the agreement, executed on July 14, 2026, LinDo has secured the exclusive rights to develop and market the Product in the Japanese market.

Developed by Proveca to treat severe sialorrhea in paediatric patients with chronic neurological disorders, the Product has been marketed in 20 countries worldwide to date, across Europe, South America and Asia, following its initial EU approval in 2016. Despite being available internationally for nearly a decade, the Product has remained inaccessible to patients in Japan due to the issue of "drug loss." ^{*1)}

Chronic sialorrhea may occur in paediatric patients with chronic neurological disorders, such as cerebral palsy; it not only reduces the patient's quality of life but also places a daily caregiving burden on families and caregivers. Furthermore, posterior sialorrhea, in which saliva flows into the pharynx, can lead to the aspiration of saliva and is known to pose a risk for serious respiratory complications such as aspiration pneumonia.

LinDo is a seed incubator founded with the purpose of establishing and expanding a "New Business Model to Overcome Drug Loss." The company develops and commercializes innovative therapies in Japan for rare and intractable diseases that are approved globally but remain yet to be developed in Japan, leaving patients without access. Facing medical needs that cannot be measured by patient population or market size alone, LinDo's mission is to bridge this gap by delivering globally created medical value to patients and their families, ultimately resolving the issue of "drug loss."

NEWS RELEASE

By in-licensing a therapy already used overseas, this partnership with Proveca will deliver a new treatment option to Japanese patients who are waiting for access, while demonstrating the feasibility of LinDo's mission to address "drug loss".

Regarding the execution of this agreement, Jun Katsura, President of LinDo, commented: "We are deeply honored to enter into this partnership with Proveca, which allows us to contribute to improve the quality of life for patients and alleviating the daily caregiving burden on their families and caregivers. While medical innovation continues to advance globally, the value generated by these innovations does not always reach everyone in need. Our vision is a society where medical choices are not limited by country or disease. Medical value is only truly realized when it reaches the hands of those who need it most. We are fully committed to driving the development of this therapy in Japan, striving for early regulatory approval to bring it to patients and their families as swiftly as possible."

Additionally, Dr. Simon Bryson, co-founder and CEO of Proveca Ltd., stated: "We are delighted to partner with LinDo to advance the development and commercialisation of Sialanar® in Japan. LinDo's commitment to addressing unmet medical needs and improving access to important therapies for patients in Japan aligns closely with Proveca's mission to deliver better medicines for children around the world. Sialanar® has already provided a valuable treatment option for children and families across numerous international markets, and we are excited by the opportunity to work with LinDo to make this therapy available to patients in Japan. This agreement represents another important milestone in our strategy to expand global access to our specialised paediatric medicines through strong regional partnerships."

*1): "Drug Loss" refers to a critical situation where innovative medicines approved globally remain unavailable in Japan due to a lack of local clinical development. Moving beyond the historical issue of "drug lag" (delayed approval), this has emerged as a severe challenge directly impacting patient access to healthcare, as patients in Japan are entirely deprived of the opportunity to receive global standard treatments. This is particularly observed in oncology, rare diseases, and pediatrics, and is widely recognized as a challenge that needs to be addressed.

References:

- Ministry of Health, Labour and Welfare: "Report of the Expert Committee on Comprehensive Measures for the Swift and Stable Supply of Pharmaceuticals" (in Japanese) (https://www.mhlw.go.jp/stf/newpage_33548.html)
- Ministry of Health, Labour and Welfare: "Report of the Committee on Regulatory Affairs for Strengthening Drug Discovery Standards and Ensuring Stable Supply" (in Japanese) (https://www.mhlw.go.jp/stf/newpage_39934.html)

NEWS RELEASE

About LinDo K.K.

At LinDo, we address vital medical needs that extend beyond mere patient numbers or market size, striving to realize a society where medical choices are not limited by country or disease. Our mission is to address the "drug loss" by in-licensing, developing, and commercializing therapies that are approved globally but remain unavailable in Japan. Through strategic partnerships both locally and worldwide, we advance our unique "New Business Model to Overcome Drug Loss," enhancing healthcare access to ensure that essential medical value reaches the people who need it most.

Corporate Website: <https://lindosi.com/>

About Proveca Ltd.

Proveca Ltd is a UK-founded pharmaceutical company, with technical and commercial operations globally. The company specialises in the development, licensing and commercialisation of evidence-based medicines to address the unmet medical needs of children, with a current paediatric product portfolio and pipeline spanning CNS and cardiology.

Corporate Website: <https://www.proveca.com/>



Left: Dr. Simon Bryson, co-founder and CEO of Proveca Ltd. Right : Jun Katsura, President of LinDo K.K.
